Restylane Lyft and Juvéderm Voluma XC are the two hyaluronic acid (HA) fillers with specific FDA approval for cheek augmentation and midface volume correction. Both are designed for deep injection — subcutaneous or supraperiosteal — to restore age-related volume loss in the midface. Both contain lidocaine to reduce injection discomfort. Both are reversible with hyaluronidase.
But they are not interchangeable. They use different manufacturing technologies, have different physical properties, last different lengths of time according to their FDA labeling, and tend to suit different clinical situations. The choice between them is one your provider should explain in terms of your anatomy, not just brand preference.
The formulations are fundamentally different
Restylane Lyft uses NASHA technology (Non-Animal Stabilized Hyaluronic Acid), developed by Galderma (originally Q-Med). NASHA produces a gel with a more granular, particulate structure. The HA particles are highly cross-linked and maintain their shape under pressure.
Juvéderm Voluma XC uses Vycross technology, developed by Allergan (now AbbVie). Vycross cross-links HA molecules of different molecular weights — high and low — producing a smoother, more cohesive gel that integrates more uniformly into tissue.
The practical difference shows up in two measurable properties:
| Property | Restylane Lyft | Juvéderm Voluma XC |
|---|---|---|
| Technology | NASHA | Vycross |
| G-prime (lifting capacity) | ~531 Pa | ~274 Pa |
| HA concentration | 20 mg/mL | 20 mg/mL |
| Cohesivity | Lower (more structured) | Higher (more integrated) |
| Contains lidocaine | Yes (0.3%) | Yes (0.3%) |
| Granulometry | Particulate | Smooth |
G-prime (G') is the most important physical difference. It measures a gel's resistance to deformation — essentially how much "lift" the filler provides. Restylane Lyft's G' is nearly double that of Voluma. This means Lyft provides more structural support per unit of volume injected. In practice, a provider may need fewer syringes of Lyft to achieve the same degree of cheek projection compared to Voluma.
Cohesivity measures how well the gel holds together rather than spreading. Voluma is more cohesive — it spreads less and integrates more smoothly into surrounding tissue. This can be advantageous in patients with thin skin where the edges of a particulate filler might be visible or palpable.
FDA-approved duration: what the labels say
The FDA-cleared duration claims come from the pivotal clinical trials each manufacturer submitted:
Restylane Lyft: FDA approved for cheek augmentation in July 2015 (PMA supplement P040024/S073). The clinical study showed that 54.3% of treated subjects were responders at 12 months. The label states duration "up to approximately 12–15 months" for cheek augmentation, with some instances lasting up to 18 months.
Juvéderm Voluma XC: FDA approved for cheek augmentation in October 2013 (PMA P110033). The pivotal study (N=345) showed responder rates of 86% at 6 months, 85% at 12 months, and 67% at 24 months in patients who received a mean injection volume of 6.8 mL. The label states duration "up to 2 years" in the cheek area.
The duration comparison is complicated by the fact that the Voluma study used substantially more total volume (mean 6.8 mL) than is typical in routine clinical practice. In real-world use, most patients receive 1–2 syringes (1–2 mL) per treatment. At those volumes, duration for both products is typically in the 12-to-18-month range, with individual variation.
Which areas each filler tends to favor
Because of the G-prime and cohesivity differences, experienced injectors tend to develop preferences based on treatment area and patient anatomy:
Where Restylane Lyft tends to be preferred:
- Significant structural lift: patients who need pronounced cheek projection or midface support may get more lift per syringe.
- Temples: the firmer gel holds its shape well in this concave area.
- Nonsurgical necklift or jawline support: the higher G' provides better structural scaffolding.
- Nose (non-surgical rhinoplasty): many injectors prefer a firmer filler for bridge contouring.
- Patients with thicker skin: the particulate texture is less likely to show through.
Where Juvéderm Voluma tends to be preferred:
- Patients with thin skin: the smoother gel is less likely to create visible edges or Tyndall effect.
- Diffuse volume replacement: when the goal is broad, even contouring rather than a specific structural lift.
- Younger patients with early volume loss: a softer result looks more natural when only subtle augmentation is needed.
- Cheeks specifically: Voluma's label is specifically for cheek augmentation, and its smooth integration tends to look natural in this area.
- Lips and perioral area: Voluma is not the right product here (Volbella or Volbella XC are), but the Vycross family is generally favored for areas requiring softness.
These are injector tendencies, not absolute rules. An experienced provider can achieve good results with either product in most midface areas. The best product depends more on the injector's skill with it and the patient's specific anatomy than on any inherent superiority of one over the other.
Cost comparison
In most US markets, Juvéderm Voluma XC costs more per syringe than Restylane Lyft:
- Restylane Lyft: typically $700–$1,000 per syringe (1 mL)
- Juvéderm Voluma XC: typically $900–$1,300 per syringe (1 mL)
The per-syringe difference is usually $100–$300. However, because Lyft provides more lift per unit volume, some providers report needing fewer syringes of Lyft to achieve the same degree of projection. In a clinical comparison, one plastic surgery practice noted that a patient requiring 2 syringes of Lyft might need 3–4 syringes of Voluma for equivalent lift.
This does not mean Lyft is universally cheaper — the total cost depends on the treatment plan, the number of areas, and the provider's pricing structure. But it is worth asking your injector whether the treatment plan calls for different volumes depending on which product is used.
Safety and adverse events
Both products have well-established safety profiles. Common side effects are similar across HA fillers:
- Swelling, bruising, redness, and tenderness at the injection site, typically resolving within a few days to a week.
- Firmness or palpable lumps, especially in the first 2 weeks after injection.
- The Tyndall effect (bluish discoloration under the skin) can occur with any HA filler injected too superficially. It is more visible with particulate fillers (Lyft) in patients with thin skin.
Serious but rare complications include vascular occlusion (blockage of a blood vessel by filler material), which can lead to tissue necrosis or, in extremely rare cases, blindness if injected in the periorbital area. The cheek is a relatively safe zone compared to the nose or glabella, but the risk is not zero. Both products are reversible with hyaluronidase, which is the emergency treatment for suspected vascular occlusion.
Ask your provider whether they keep hyaluronidase on hand and have a protocol for managing vascular events. This is a basic safety question that separates prepared practices from unprepared ones.
Clinical trial data: what the FDA saw
The FDA's Summary of Safety and Effectiveness Data (SSED) for each product provides the most rigorous comparison:
Restylane Lyft cheek augmentation trial (P040024/S073):
- 200 subjects (150 treated, 50 no-treatment control)
- Primary endpoint: ≥1-grade improvement on Medicis Midface Volume Scale at 2 months
- Responder rate: 88.7% (treated) vs. 16.7% (control)
- At 12 months: 54.3% remained responders
- Approved for patients over 21
Juvéderm Voluma XC cheek augmentation trial (P110033):
- 345 subjects (299 randomized, 238 treated)
- Primary endpoint: ≥1-grade improvement on Mid-Face Volume Deficit Scale at 6 months
- Responder rate at 6 months: 86%
- Responder rate at 12 months: 85%
- Responder rate at 24 months: 67% (at mean 6.8 mL total volume)
- Approved for patients over 21
The different responder rates at 12 months (54% vs. 85%) do not directly compare the products — the studies used different scales, different injection volumes, and different responder definitions. They should not be used to claim one product outperforms the other.
A newer alternative: Restylane Contour
In 2021, Galderma received FDA approval for Restylane Contour, a cheek-augmentation filler that uses XpresHAn Technology (Optimal Balance Technology) rather than NASHA. It is designed to integrate with natural facial movement while restoring midface volume. In its pivotal trial, patients treated with Restylane Contour required less total volume (4.26 mL vs. 4.88 mL for the comparator) and more than 91% were satisfied at 48 weeks.
Restylane Contour occupies a different position from Lyft: it is softer and more flexible, designed for a more dynamic, natural-feeling result rather than maximal structural lift. If you are choosing between Lyft and Voluma specifically for cheek augmentation, ask your provider whether Contour might be a better option for your goals — particularly if you want a result that moves naturally with facial expression.
When neither is right
Not every patient with midface volume loss is best served by HA filler:
- Significant skin laxity without volume deficit may respond better to skin-tightening devices or surgical intervention.
- Active inflammatory skin conditions in the treatment area are a reason to defer.
- Known hypersensitivity to HA or lidocaine is a contraindication.
- Patients seeking permanent correction should understand that HA fillers are temporary by design. Biostimulators (Sculptra) or surgical options may be more appropriate for long-term goals.
- Budget constraints: if the cost of 2–3 syringes of either product is prohibitive, discuss whether a staged approach or a different treatment category makes more sense.
Sources
FDA Summary of Safety and Effectiveness Data: Restylane Lyft with Lidocaine for cheek augmentation (P040024/S073). https://www.accessdata.fda.gov/cdrh_docs/pdf4/P040024S073b.pdf
FDA Summary of Safety and Effectiveness Data: Juvéderm Voluma XC (P110033). https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033b.pdf
Restylane Lyft with Lidocaine, full prescribing information. Galderma Laboratories. https://www.accessdata.fda.gov/cdrh_docs/pdf4/P040024S099D.pdf
Juvéderm Voluma XC, full prescribing information. Allergan. https://www.accessdata.fda.gov/cdrh_docs/pdf11/p110033c.pdf
FDA Executive Summary: General Issues Panel Meeting on Dermal Fillers (listing all approved HA fillers and their indications). https://www.fda.gov/media/188185/download
Premarket Approval (PMA) database entry for Juvéderm Voluma XC (P110033). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110033
